VDAC1 and neoplasm: Similar to sorafenib, erastin has been recognized as xCT inhibitor with shown efficacy against tumor cell lines.8 Next to impairing amino acids’ transport over the membrane, erastin disrupts mitochondrial permeability transition pore (mPTP) and targets the voltage-dependent anion channel 1 (VDAC-1), mechanisms by which erastin could directly interfere with the mitochondrial energy supply of the cells.28,29,30 Metabolically highly active cells such as tumor cells will rapidly be depleted of required substrates and can no longer maintain cell integrity.